Uncategorized
Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2017, along with a general business update. Aerie Highlights All programs for our product candidates remain on track, with the RhopressaTM (netarsud